here what makes me made From LAST NEWS MARCH 13 5:03 pM
Aurinia Pharmaceuticals stock climbed 22%, building from more modest gains last week. The maker of the experimental lupus drug voclosporin has seen its shares nearly triple since the end of February, and last week's major catalyst was the announcement that Aurinia would present data from voclosporin's phase 2b trial at April's National Kidney Foundation spring meetings. The company later reported that voclosporin would enter phase 3 testing in the second quarter of this year, spurring further speculation that the drug could be a strong performer in treating lupus if its autoimmune-enhancing properties continue to appear. It's obviously too early to be certain if the stock will live up to its full potential, but right now, investors seem happy about the prospects that Aurinia has with voclosporin going forward.
READ LAST SECTION OF THIS NEWS...
Not long ago Motley had an article about how for the first time everyone at Mottley aggreed on the incredible potential of this stock...BUT NOW... It's obviously too early to be certain if the stock will live up to its full potential.
Who care us investor we have an unlimited found to finance all kinds....Bull...